Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia

Khaled Awad, MD

Status and phase

Terminated

Early Phase 1

Conditions

Ventricular Tachycardia

Treatments

Drug: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02962076

F141013002

Details and patient eligibility

About

Imaging is to be performed prior to procedure using positron emission tomography/ computed tomography (PET/CT), after a special dye is injected. The scans are going to be merged with other cardiac scans when doing the ablation procedure to correlate anatomy with physiology.

Enrollment

11 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical indication for ventricular tachycardia (VT) ablation (at least one clinical episode of sustained VT) despite antiarrhythmic drug therapy, or if the patient does not wish to be on one
Ischemic or nonischemic cardiomyopathy
Sustained monomorphic VT

Exclusion criteria

Right ventricular VT
Polymorphic VT or ventricular fibrillation (VF) being the sole detected clinical arrhythmia
Patient is unable to sign informed consent
Recent myocardial infarction less than 30 days
Recent ablation for ventricular tachycardia less than 30 days
Patient is unwilling or unable to cooperate with the study
Prosthetic mitral or aortic valve
General contraindications to VT ablation, e.g., major contraindication to anticoagulation therapy, known presence of left ventricular thrombus, reversible causes of VT or VF
General contraindications to PET imaging, e.g., pregnancy or lactation
General contraindication to magnetic resonance imaging or to the administration of gadolinium.
Contraindication to the placement of hemodynamic support devices, i.e. the presence of mechanical valves or lack of adequate vascular access